Primera ushers in a new era for G.I. research and development. We have identified two factors that add an enormous expense to clinical trials. The first is a delay in site initiation and activation and the second is subject randomization. Our team’s expertise and leadership position in the G.I. community has created our unique clinical network. Additionally, we offer teaching strategies that will aid investigators and their staff in the identification and retention of subjects.
We are diverse in all areas of gastrointestinal ailments. Our experience on the research side has led to the development and FDA approval of medications that treat GERD, IBS, IBD (including both Crohn’s and UC ), EOE, iron deficiency anemia, CIC, and OIC. Additionally, we have sponsored our own research investigating new indications of existing medications in the management of esophageal and gastric motility disorders.